Shandong Pharmaceutical Glass Co. (600529) Fair Value & Analysis
Consumer Cyclical · CN · Market cap 12.8B CNY
Fair value as of: Aug 8, 2026
From 26 valuation models · updated 2 days ago
Fair value updated Aug 8, 2026, revised from ¥22.80 to ¥21.44 (−6.0%) since Jul 11, 2026. Share price +6.0% over the past month.
A solid business, screening 11% undervalued on our models.
What matters now
- A fairly wide model range (¥12.23 to ¥28.42) leaves room in how you read the outcome.
- Our model range runs from ¥12.23 (bear) to ¥28.42 (bull), base ¥21.44. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 58/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 8, 2026.
How to read this chart
60‑month range ¥17.33 – ¥43.74 · fair‑value band ¥12.23 – ¥28.42 · the ¥19.32 price screens below the ¥21.44 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 8, 2026.
Analysis
Shandong Pharmaceutical Glass Co. (600529) currently trades at ¥19.32, while our model-based Fair Value estimate is ¥21.44, implying the stock looks roughly 11.0% undervalued today. The Quality Score stands at 58/100 (solid quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Shandong Pharmaceutical Glass Co. generated revenue of 4.5B CNY at a net margin of 14.8%. Revenue grew 4.1% year over year. It earns a return on equity of 8.0%. The balance sheet holds a net cash position of 1.1B CNY. Fundamentals as of Aug 8, 2026
Our scenario range runs from ¥12.23 (bear case) to ¥28.42 (bull case); at ¥19.32, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 19% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Cyclical peers we cover trades at -22% fair-value upside, at 11%, 600529 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥20.91) versus Asset-Based (¥8.37). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 8, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 48
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shandong Pharmaceutical Glass Co.Ltd engages in research and development, production, and sale of various pharmaceutical glass packaging products in China.
Full company description
Shandong Pharmaceutical Glass Co.Ltd engages in research and development, production, and sale of various pharmaceutical glass packaging products in China. The company offers moulded glass products, including amber glass containers, dropper bottles, infusion bottles, cosmetic bottles, tablet bottle, food glass, cobalt blue and green bottles, and black bottles, as well as moulded glass injection vial comprising type I/II/III. It also provides tubular glass products, such as glass tubes for pharma use, other tubular bottle with screw neck finish, PFS and glass cartridges, tubular glass vials for injection, and ampoules. In addition, the company offers closures for glass containers comprising plastic bottles, dropper cap, plastic cap for bottles, plunger and combiseal for glass cartridge, teflon coated rubber stopper, rubber stopper for injection vial/bottle, accessories for PFS, and flip off cap and Al-seal. Further, it provides butyl rubber stopper for injection; and prefilled syringe, aluminum plastic multi-cap, plastic dropper cap, dropper, caps for dropper bottle, and white HDPE bottles. The company also exports its products to to Europe, the United States, Russia, Japan, Korea, Southeast Asia, and internationally. Shandong Pharmaceutical Glass Co.Ltd was founded in 1970 and is based in Zibo, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shandong Pharmaceutical Glass Co. reported revenue of ¥4.5B in FY2025 versus ¥3.9B in FY2021, a compound +3.7%/yr. Reported net income was ¥690M in FY2025, compounding +3.9%/yr from FY2021.
Watch 600529: get an alert when its fair value changes →
Peer Group
Packaging & Containers · 273 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Packaging & Containers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Packaging & Containers stocks, each showing price versus our Fair Value estimate (as of Aug 8, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Stora Enso Oyj STER | kr 101.90 | kr 126.39 | +24% |
| ShenZhen YUTO Packaging Technology Co 002831 | ¥29.10 | ¥20.88 | -28% |
| SCG Packaging Public Company SCGP | 29.00 THB | 16.12 THB | -44% |
| AblePrint Technology Co 7734 | 2,850 TWD | 661.69 TWD | -77% |
| PT Fajar Surya Wisesa Tbk, FASW | 5,312 IDR | 1,194 IDR | -78% |
| Taiwan Hon Chuan Enterprise Co 9939 | 132.50 TWD | 127.06 TWD | -4% |
| Time Technoplast Limited TIMETECHNO | ₹206.82 | ₹161.42 | -22% |
| EPL Limited 500135 | ₹222.25 | ₹111.65 | -50% |
| Ton Yi Industrial Corp 9907 | 15.15 TWD | 23.17 TWD | +53% |
| Dongwon Systems Corporation 014820 | 19,330 KRW | 31,473 KRW | +63% |
Compare Shandong Pharmaceutical Glass Co. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is Shandong Pharmaceutical Glass Co. (600529) overvalued or undervalued?
What is the fair value of 600529?
What is the quality score of 600529?
What is the revenue of Shandong Pharmaceutical Glass Co. (600529)?
What is the net profit margin of 600529?
Does Shandong Pharmaceutical Glass Co. pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shandong Pharmaceutical Glass Co. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.